Upgraded Mediterranean Diet With Exercise Cuts Diabetes Risk by 31%
A major 6-year European trial found a calorie-reduced Mediterranean diet plus exercise slashed type 2 diabetes risk by nearly a third.
Summary
A large Spanish clinical trial called PREDIMED-Plus followed nearly 5,000 adults at metabolic risk for six years. Participants who combined a calorie-reduced Mediterranean diet with moderate exercise and professional coaching were 31% less likely to develop type 2 diabetes compared to those following a standard Mediterranean diet alone. The intervention group also lost significantly more weight — 3.3 kg on average — and reduced waist circumference by 3.6 cm. Researchers estimated the program prevented roughly three diabetes cases per 100 participants. Published in Annals of Internal Medicine, this is one of the most rigorous nutrition trials ever conducted in Europe, offering strong clinical evidence that structured lifestyle changes can meaningfully delay or prevent one of the world's most common metabolic diseases.
Detailed Summary
Type 2 diabetes affects hundreds of millions of people globally and is strongly linked to shortened healthspan and accelerated aging. The PREDIMED-Plus trial, the largest nutrition study ever conducted in Europe, now provides some of the strongest evidence to date that a structured lifestyle intervention can dramatically reduce diabetes risk in high-risk adults.
The trial enrolled 4,746 adults aged 55 to 75, all with overweight or obesity and metabolic syndrome but no existing diabetes or cardiovascular disease. Over six years, one group followed a calorie-reduced Mediterranean diet — roughly 600 fewer calories per day — combined with moderate physical activity including brisk walking, strength training, and balance exercises, plus professional weight-loss coaching. The control group followed a traditional Mediterranean diet without calorie or exercise modifications.
The results were striking. The intervention group was 31% less likely to develop type 2 diabetes. They lost an average of 3.3 kg and reduced waist circumference by 3.6 cm, compared to just 0.6 kg and 0.3 cm in the control group. In practical terms, the program prevented approximately three diabetes cases per 100 participants — a meaningful number when scaled to population level.
What makes these findings particularly valuable is the study design. PREDIMED-Plus ran for six years across more than 100 primary care centers in Spain, involved over 200 researchers, and was funded with more than 15 million euros. Results were published in the prestigious Annals of Internal Medicine, lending them high scientific credibility.
For health-conscious individuals, the takeaway is clear: the Mediterranean diet works better as a platform for metabolic protection when paired with modest calorie reduction, consistent movement, and accountability. No single exotic supplement is needed — structured adherence to proven lifestyle pillars produces clinically significant outcomes for one of the most prevalent age-related diseases.
Key Findings
- A calorie-reduced Mediterranean diet plus exercise cut type 2 diabetes risk by 31% over six years
- Intervention participants lost 3.3 kg and reduced waist circumference by 3.6 cm versus minimal change in controls
- Program prevented approximately 3 diabetes cases per 100 high-risk participants over the study period
- Adding 600 kcal daily deficit and moderate exercise significantly amplified standard Mediterranean diet benefits
- Professional coaching and structured support were key components driving the intervention's superior outcomes
Methodology
This is a research summary reporting on a peer-reviewed randomized clinical trial published in Annals of Internal Medicine. PREDIMED-Plus is a large, well-funded multi-center trial involving over 200 researchers across 23 Spanish institutions, considered high-credibility evidence. The six-year follow-up and nearly 5,000 participants provide substantial statistical power.
Study Limitations
The article is a summary and the full trial data in Annals of Internal Medicine should be reviewed for subgroup analyses and dropout rates. Participants were Spanish adults aged 55–75 with metabolic syndrome, so generalizability to younger or non-European populations requires caution. Long-term effects beyond six years and cardiovascular outcomes from PREDIMED-Plus are not addressed in this summary.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.